Sugi Predict

Sugi Predict / Compounds / SCHEMBL1044548

SCHEMBL1044548

SCHEMBL1044548

COC(=O)c1cc(F)c(Br)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.49
▸ CA2 P00918 5/20 0.49
▸ CA9 Q16790 5/20 0.49
▸ CA12 O43570 4/20 0.49
▸ CA7 P43166 4/20 0.49
▸ CA14 Q9ULX7 4/20 0.49
▸ PDK2 Q15119 1/20 0.49
▸ PDK4 Q16654 1/20 0.49
▸ GAA P10253 2/20 0.46
▸ SOS1 Q07889 1/20 0.44
▸ LMNA P02545 4/20 0.44
▸ XDH P47989 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ FUT7 Q11130 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1977588 0.93 CA1 (0.49) CA1CA2CA9CA12CA7
SCHEMBL31394743 0.87 SOS1 (0.51) CA1CA2CA9CA12CA7
SCHEMBL26580321 0.86 CA1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL1044961 0.85 SOS1 (0.46) CA1CA2CA9CA12CA7
SCHEMBL2551270 0.85 CA12 (0.55) CA1CA2CA9CA12CA7
SCHEMBL20802853 0.83 CA1 (0.53) CA1CA2CA9CA12CA7
SCHEMBL31746616 0.82 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL15795968 0.82 SOS1 (0.44) CA1CA2CA9CA12CA7
SCHEMBL31079873 0.81 SOS1 (0.50) CA1CA2CA9CA12CA7
SCHEMBL365953 0.81 SOS1 (0.50) CA1CA2CA9CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741389-A1 KAT6 INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2026-05-13 — — EP disclosed
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-10-14 — — US disclosed
US-20250171457-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-05-29 — — US disclosed
US-20250122212-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 — — US disclosed
WO-2025078808-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2025-04-17 — — WO disclosed
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-04-10 — — US disclosed
US-20250084093-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-03-13 — — US disclosed
CN-114616226-B Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders TMEM16A有限公司 2025-03-04 — — CN disclosed
WO-2025007873-A1 KAT6 INHIBITOR 上海齐鲁制药研究中心有限公司 2025-01-09 — — WO disclosed
EP-4486390-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF Terremoto Biosciences, Inc (US) 2025-01-08 — — EP disclosed
WO-2018210987-A1 BENZOFURANE AND BENZOTHIOPHENE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-11-22 — — WO disclosed
WO-2018148204-A1 ASK1 INHIBITING AGENTS BIOGEN MA INC. (US) 2018-08-16 — — WO disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 — — US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 — — US disclosed
US-8492372-B2 Modulators of dopamine neurotransmission INTEGRATED RESEARCH LABORATORIES SWEDEN AB (SE) 2013-07-23 — — US disclosed
EP-2271638-B1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2011-08-31 — — EP disclosed
US-20110112065-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2011-05-12 — — US disclosed
CN-102015674-A Modulators of dopamine neurotransmission NSAB AF NEUROSEARCH SWEDEN AB 2011-04-13 — — CN disclosed
EP-2271638-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) 2011-01-12 — — EP disclosed
WO-2009133110-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2009-11-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT1S1, AKT2 CA1 3828/4885CA2 4004/4885CA9 4276/4885
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect KEAP1, NFE2L2, BACH1 CA1 2037/4885CA2 798/4885CA9 3010/4885
US-20110112065-A1 MODULATORS OF DOPAMINE NEUROTRANSMISSION SLC18A2, SYNGR2, DBH CA1 4126/4885CA2 3891/4885CA9 4831/4885
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP CA1 2217/4885CA2 2263/4885CA9 652/4885
US-20250122212-A1 NOVEL COMPOUNDS CYP11B1, CYP11B2, UGT1A1 CA1 1755/4885CA2 3686/4885CA9 1172/4885
US-20250171457-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT KEAP1, NFE2L2, BACH1 CA1 2037/4885CA2 798/4885CA9 3010/4885
US-20250084093-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT KEAP1, NFE2L2, BACH1 CA1 1968/4885CA2 761/4885CA9 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.